Synthesis, anti-HIV and antitubercular activities of nelfinavir diester derivatives

Biomedicine and Pharmacotherapy

Volumn 62, Issue 1, 2008, Pages 1-5

  Sriram, Dharmarajan ^a   Yogeeswari, Perumal ^a   Dinakaran, Murugesan ^a   Sowmya, Mannila ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Anti HIV activity; Antitubercular activity; Nelfinavir

Indexed keywords

2 [3' (PHENYLTHIOMETHYL) 4' AZA 5' OXO 5 (2''METHYLPHENYL)PENTYL]DECAHYDROISOQUINOLINE 3 N TERT BUTYLCARBOXAMIDE; 2',3'' BIS(5 NITROFURAN 2 CARBOYLATE)ESTER; 2',3'' BIS(PIVALOYL)ESTER; 2',3'' DIISONICOTINATE ESTER OF 2 [3' (PHENYLTHIOMETHYL) 4' AZA 5' OXO 5 (2'' METHYLPHENYL)PENTYL]DECAHYDROISOQUINOLINE 3 N TERTBUTYLCARBOXAMIDE; 4 DIMETHYLAMINO PYRIDINE; ALIPHATIC CARBOXYLIC ACID; ANTIVIRUS AGENT; AROMATIC CARBOXYLIC ACID; CARBOXYL GROUP; CYANAMIDE; DICYLOHEXYL CARBODIIMIDE; NELFINAVIR; NELFINAVIR DIESTER DERIVATIVE; PYRIDINE DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

AGAR DILUTION; ANTIVIRAL ACTIVITY; ARTICLE; CATALYST; DRUG ACTIVITY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROBIAL ACTIVITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CELL LINE; ESTERS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NELFINAVIR;

EID: 38049040718     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.08.002     Document Type: Article

References (10)

1. Hsu J.T., Wang H.C., Chen G.W., and Shih S.R. Antiviral drug discovery targeting to viral proteases. Curr Pharm Des 12 (2006) 1301-1314
2. Stephen W.K., Vincent J.K., Jay F.D., Bhasker V.S., James E.F., Krzysztof A., et al. Viracept (Nelfinavir Mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem 40 (1997) 3979-3985
3. Bilello J.A., Bilello P.A., Stellrecht K., Leonard J., Norbeck D.W., Kempf D.J., et al. Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 40 (1996) 1491-1497
4. Nascimbeni M., Lamotte C., Peytavin G., Farinotti R., and Clavel F. Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Antimicrob Agents Chemother 43 (1999) 2629-2634
5. Dye C., Scheele S., Dolin P., Pathania V., and Raviglione M.C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282 (1999) 677-686
6. Selwyn P.A., Hartel D., Wasserman W., and Drucker E. Impact of the AIDS epidemic on morbidity and mortality among intravenous drug users in a New York City methadone maintenance program. Am J Public Health 79 (1989) 1358-1362
7. Daley C.L., Small P.M., and Schecter G.F. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 326 (1992) 231-235
8. Sriram D., and Yogeeswari P. Towards the design and development of agents with broad spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS. Curr Med Chem 10 (2003) 1689-1716
9. Sriram D., Srichakravarthy N., Bal T.R., and Yogeeswari P. Synthesis of zidovudine prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS. Biomed Pharmacother 59 (2005) 452-455
10. Sriram D., Yogeeswari P., Srichakravarthy N., and Bal T.R. Synthesis of stavudine amino acid ester prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS. Bioorg Med Chem Lett 14 (2004) 1085-1087